Nuformix PLC Director/PDMR Shareholding - Replacement (0484M)

TIDMNFX

RNS Number : 0484M

Nuformix PLC

16 September 2021

The following amendments have been made to the ' Director/PDMR Shareholding ' announcement released on 16/09/2021 at 12:47 p.m. under RNS No 0420M.

The price paid was 1.35 pence, not 0.0135 pence.

All other details remain unchanged.

16 September 2021

Nuformix plc

("Nuformix" or the "the Company")

Director/PDMR Shareholding

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell purchased 350,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.35 pence per share on 16 September 2021.

- Ends -

Enquiries:

 
  Nuformix plc                               [phone] 
 Dr Anne Brindley, CEO 
 
 Allenby Capital Limited                     [phone] 
 Nick Athanas / George Payne (Corporate 
  Finance) 
 Stefano Aquilino / Matt Butlin (Sales 
  & Corporate Broking) 
 
 Walbrook PR                                 [phone] 
  Anna Dunphy / Paul McManus                [e-mail] 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                          Dr Alastair Riddell 
     ----------------------------  ------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status               PDMR - Chairman 
     ----------------------------  ------------------------------------- 
 b)   Initial notification          Initial notification 
       /Amendment 
     ----------------------------  ------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                          Nuformix plc 
     ----------------------------  ------------------------------------- 
 b)   LEI                           2138003XG3H3I2J3BJ24 
     ----------------------------  ------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the            Ordinary Shares of nominal value 
       financial instrument,         0.1 pence each 
       type of instrument 
 
       Identification code           GB00BYW79Y38 
     ----------------------------  ------------------------------------- 
 b)   Nature of the transaction     Purchase of Ordinary Shares 
     ----------------------------  ------------------------------------- 
 c)   Price(s) and volume(s)          Price(s)   Volume(s) 
                                       1.35p      350,000 
                                                 ---------- 
     ----------------------------  ------------------------------------- 
 d)   Aggregated information 
 
       - Aggregated volume            350,000 
 
       - Price                        1.35p 
 
       - Total                        GBP4,725.00 
     ----------------------------  ------------------------------------- 
 e)   Date of the transaction       16 September 2021 
     ----------------------------  ------------------------------------- 
 f)   Place of the transaction      London Stock Exchange, Main Market 
     ----------------------------  ------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKABDNBKDDCD

(END) Dow Jones Newswires

September 16, 2021 09:14 ET (13:14 GMT)